FDMT — 4D Molecular Therapeutics Share Price
0.000.00%
Last trade - 00:00- $201.51m
- -$119.92m
- $0.04m
- 40
- 26
- 29
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.34 | ||
| Price to Tang. Book | 0.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6,928.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.59% | ||
| Return on Equity | -32.97% | ||
| Operating Margin | -884026.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.61 | 18.04 | 3.13 | 20.72 | 0.04 | 5.47 | 4.77 | -64.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Directors
- John Milligan CHM (60)
- David Kirn CEO (59)
- August Moretti CFO (71)
- Robert Fishman OTH (59)
- Carolyne Zimmermann OTH
- David Schaffer DRC (50)
- Tony Yao DRC (49)
- Jacob Chacko IND (42)
- Susannah Gray IND (60)
- Nancy Miller-Rich IND (62)
- Charles Theuer IND (57)
- Shawn Tomasello IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 11th, 2015
- Public Since
- December 11th, 2020
- No. of Shareholders
- 13
- No. of Employees
- 227
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 46,324,642
- Address
- 5858 Horton Street #455, Emeryville, EMERYVILLE, 94608
- Web
- https://4dmoleculartherapeutics.com/
- Phone
- +1 5105052680
- Contact
- Julian Pei
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for FDMT
4D Molecular Therapeutics Inc Annual Shareholders Meeting
4D Molecular Therapeutics Inc Annual Shareholders Meeting
Q2 2025 4D Molecular Therapeutics Inc Earnings Release
Q3 2025 4D Molecular Therapeutics Inc Earnings Release
Q3 2025 4D Molecular Therapeutics Inc Earnings Release
Similar to FDMT
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
Acelyrin
NASDAQ Global Select Market
FAQ
What is the 4D Molecular Therapeutics share price?
As of Today at 19:00 UTC, shares in 4D Molecular Therapeutics are trading at $3.44. This share price information is delayed by 15 minutes.
How has the 4D Molecular Therapeutics share price performed this year?
Shares in 4D Molecular Therapeutics last closed at $3.44 and the price had moved by -86.58% over the past 365 days. In terms of relative price strength the 4D Molecular Therapeutics share price has underperformed the S&P500 Index by -88.06% over the past year.
What are the analyst and broker recommendations for 4D Molecular Therapeutics?
The overall consensus recommendation for 4D Molecular Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the 4D Molecular Therapeutics dividend yield?
4D Molecular Therapeutics does not currently pay a dividend.
Does 4D Molecular Therapeutics pay a dividend?
4D Molecular Therapeutics does not currently pay a dividend.
When does 4D Molecular Therapeutics next pay dividends?
4D Molecular Therapeutics does not currently pay a dividend.
How do I buy 4D Molecular Therapeutics shares?
To buy shares in 4D Molecular Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 4D Molecular Therapeutics?
As of the previous close price of $3.44, shares in 4D Molecular Therapeutics had a market capitalisation of $159.36m.
Where are 4D Molecular Therapeutics shares listed?
Here are the trading details for 4D Molecular Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: FDMT
What kind of share is 4D Molecular Therapeutics?
Based on an overall assessment of its quality, value and momentum 4D Molecular Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 4D Molecular Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in 4D Molecular Therapeutics is $28.20. That is 719.77% above the last closing price of $3.44.
Analysts covering 4D Molecular Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.53 for the next financial year.
Find out moreWhat is the trend in the 4D Molecular Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4D Molecular Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -61.47%.
As of the last closing price of $3.44, shares in 4D Molecular Therapeutics were trading -54.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 4D Molecular Therapeutics PE Ratio?
The 4D Molecular Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 4D Molecular Therapeutics?
4D Molecular Therapeutics' management team is headed by:
- John Milligan - CHM
- David Kirn - CEO
- August Moretti - CFO
- Robert Fishman - OTH
- Carolyne Zimmermann - OTH
- David Schaffer - DRC
- Tony Yao - DRC
- Jacob Chacko - IND
- Susannah Gray - IND
- Nancy Miller-Rich - IND
- Charles Theuer - IND
- Shawn Tomasello - IND